250 related articles for article (PubMed ID: 21962468)
1. Adolescent and young adult HPV vaccination in Australia: achievements and challenges.
Garland SM; Skinner SR; Brotherton JM
Prev Med; 2011 Oct; 53 Suppl 1():S29-35. PubMed ID: 21962468
[TBL] [Abstract][Full Text] [Related]
2. HPV vaccination catch up program - utilisation by young Australian women.
Weisberg E; Bateson D; McCaffery K; Skinner SR
Aust Fam Physician; 2009; 38(1-2):72-6. PubMed ID: 19283241
[TBL] [Abstract][Full Text] [Related]
3. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.
Brotherton J; Gertig D; Chappell G; Rowlands L; Saville M
Commun Dis Intell Q Rep; 2011 Jun; 35(2):197-201. PubMed ID: 22010515
[TBL] [Abstract][Full Text] [Related]
4. The Australian experience with the human papillomavirus vaccine.
Garland SM
Clin Ther; 2014 Jan; 36(1):17-23. PubMed ID: 24417782
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
[TBL] [Abstract][Full Text] [Related]
6. Will vaccinated women attend cervical screening? A population based survey of human papillomavirus vaccination and cervical screening among young women in Victoria, Australia.
Brotherton JM; Mullins RM
Cancer Epidemiol; 2012 Jun; 36(3):298-302. PubMed ID: 22204834
[TBL] [Abstract][Full Text] [Related]
7. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia.
Watson M; Shaw D; Molchanoff L; McInnes C
Aust N Z J Public Health; 2009 Aug; 33(4):365-70. PubMed ID: 19689598
[TBL] [Abstract][Full Text] [Related]
8. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia.
Smith MA; Lew JB; Walker RJ; Brotherton JM; Nickson C; Canfell K
Vaccine; 2011 Nov; 29(48):9112-22. PubMed ID: 21419773
[TBL] [Abstract][Full Text] [Related]
9. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer.
Julius JM; Ramondeta L; Tipton KA; Lal LS; Schneider K; Smith JA
Pharmacotherapy; 2011 Mar; 31(3):280-97. PubMed ID: 21361739
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
11. HPV vaccination - a paradigm shift in public health.
May J
Aust Fam Physician; 2007 Mar; 36(3):106-11. PubMed ID: 17339969
[TBL] [Abstract][Full Text] [Related]
12. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Oliphant J; Perkins N
N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
[TBL] [Abstract][Full Text] [Related]
14. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia.
Brotherton JM; Deeks SL; Campbell-Lloyd S; Misrachi A; Passaris I; Peterson K; Pitcher H; Scully M; Watson M; Webby R
Commun Dis Intell Q Rep; 2008 Dec; 32(4):457-61. PubMed ID: 19374275
[TBL] [Abstract][Full Text] [Related]
15. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Villa LL
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S17-25. PubMed ID: 18162241
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007.
Jain N; Euler GL; Shefer A; Lu P; Yankey D; Markowitz L
Prev Med; 2009 May; 48(5):426-31. PubMed ID: 19100762
[TBL] [Abstract][Full Text] [Related]
17. Acceptability and uptake of HPV vaccine in Argentina before its inclusion in the immunization program: a population-based survey.
Arrossi S; Maceira V; Paolino M; Sankaranarayanan R
Vaccine; 2012 Mar; 30(14):2467-74. PubMed ID: 22266289
[TBL] [Abstract][Full Text] [Related]
18. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
19. Protecting our patients from HPV and HPV-related diseases: the role of vaccines.
Mahoney MC
J Fam Pract; 2006 Nov; Suppl():10-7. PubMed ID: 17366753
[TBL] [Abstract][Full Text] [Related]
20. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]